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Recommendations for Standards Regarding Preclinical
Neuroprotective and Restorative Drug Development
Stroke Therapy Academic Industry Roundtable (STAIR)
Abstract—The plethora of failed clinical trials with neuroprotective drugs for acute ischemic stroke have raised justifiable
concerns about how best to proceed for the future development of such interventions. Preclinical testing of
neuroprotective drugs is an important aspect of assessing their therapeutic potential, but guidelines concerning how to
perform preclinical development of purported neuroprotective drugs for acute ischemic stroke are lacking. This
conference of academicians and industry representatives was convened to suggest such guidelines for the preclinical
evaluation of neuroprotective drugs and to recommend to potential clinical investigators the data they should review to
reassure themselves that a particular neuroprotective drug has a reasonable chance to succeed in an appropriately
designed clinical trial. Without rigorous, robust, and detailed preclinical evaluation, it is unlikely that novel
neuroprotective drugs will prove to be effective when tested in large, time-consuming, and expensive clinical trials.
Additionally, similar recommendations are provided for drugs with the potential to enhance recovery after acute
ischemic stroke, a burgeoning new field with great potential but little currently available data. The suggestions contained
in this document are meant to serve as overall guidelines that must be adapted to the individual characteristics related
to particular drugs and their preclinical and clinical development needs. (Stroke. 1999;30:2752-2758.)
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Ischemic stroke is a major cause of death and disability inthe United States, and several potential therapies were
intensively investigated over the past decade. Ischemic stroke
affects more than 500 000 individuals per year in the United
States, being the leading cause of quality-adjusted life-years
lost.1 The fact that the loss of quality-adjusted life-years
caused by stroke is greater than that of any other disease
implies that the economic burden of stroke to humankind is
also great. Although most strokes occur in older patients,
there has been an alarming increase in stroke incidence in
patients between 45 and 65 years of age.2 Despite much
animal research concerning the pathophysiology of focal
ischemic brain injury, little of this work has translated into
effective treatment modalities for stroke in humans.3 Multiple
mechanisms of brain injury from stroke related to oxygen
deprivation have been identified. These include production of
oxygen free radicals (lipid peroxidation), release of excitatory
amino acids (glutamate and aspartate), release of mediators of
inflammation, involvement of calcium, failure of energy
metabolism, and other mechanisms.4 Some may even be
overlapping. Currently, 2 thrombolytic therapy trials have
shown efficacy for improving outcome after ischemic stroke,
the NINDS t-PA trial, with intravenous tissue plasminogen
activator (TPA) given within 3 hours of stroke onset, and the
PROACT-2 trial, with intra-arterial pro-urokinase given
within 6 hours.5,6 Additionally, the defibrinogenating agent
ancrod demonstrated benefit (when initiated within 3 hours of
stroke onset) in a clinical trial.7
The idea of protecting brain tissue from injury (neuroprotec-
tion) is not a new concept. Many neuroprotective agents and
strategies were studied in the past, for example, free radical
scavengers, excitatory amino acid antagonists, hypothermia,
barbiturates, calcium channel blockers, growth factors, and
others have been investigated for years. What remains curious is
that although many of these agents appear quite effective in
preclinical studies with small-animal models of ischemia (rats,
mice, or gerbils), none of these have proven conclusively to be
effective in humans.8 Precisely why neuroprotectants that are
effective in animal models are not effective in humans is unclear.
Possible reasons relate to properties of the drugs themselves or
the specific animal models used to assess them. For example, the
free radical scavenger tirilazad mesylate was mainly effective in
reperfusion stroke models, but negative clinical trials probably
included reperfused and nonreperfused patients.8 Another novel
approach to treatment of acute ischemic stroke is administration
of restorative drugs that may enhance recovery. Animal studies
demonstrate that several agents initiated days after the onset of
experimental stroke improve the long-term functional out-
come.9,10 The purpose of this statement by a group with
expertise in the preclinical assessment of stroke therapies is to
propose recommendations for ways to optimally preclinically
assess neuroprotective and restorative drugs for acute ischemic
stroke. Additionally, recommendations will be provided to
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clinicians for assessment of preclinical data provided by the
study sponsor when considering participation in a phase II or III
clinical trial.
Dose of Drug Used
The application of agents that show putative efficacy in
nonhuman cerebral injury models to patients has exposed
significant limitations. Some pharmacological agents have
been demonstrated to be successful or not at a particular dose,
but in many cases dose-response curves were not generated.
A drug dose effective in the mouse or rat may not be effective
in large animals and/or humans. It may not be sufficient or
correct to merely scale up the dose of a drug in milligrams per
kilogram from the mouse to larger animals and humans.
Pharmacokinetics and pharmacodynamics may vary consid-
erably among species. In this regard, the generation of
dose-response curves is critical in both small-animal and
large-animal models. Some pharmacological agents may be
effective at low doses, others at higher doses, and some
agents may be effective in the middle dose range but not at
low or high doses.11 Dose-response curves involving a variety
of outcome measures after ischemia should be performed in
several species. Another aspect to consider is that neuropro-
tective drug dose ranges and toxicities in animals may not
overlap with those tolerated in humans.12 In addition, dose-
response curves may be very steep in anti-ischemia efficacy
studies. The blood-brain barrier, low cerebral blood flow
(CBF) (ie, the drug delivery system to the tissue at risk), and
plasma protein binding may present impediments for deter-
mination of appropriate dosing regimens for use in humans.
Nevertheless, there should be a target concentration, a tissue
level of effect identified from animal studies, or a surrogate
marker that will give some indication, when the drug is given
to humans, of whether there is a reasonable prospect of
achieving neuroprotection in human clinical trials.
Window of Opportunity
Another factor to consider is the period of time after the
ischemic event that drug initiation may be effective, that is,
the window of opportunity or therapeutic time window.13 The
window of therapeutic opportunity in animal models is not
necessarily predictive of the time window in humans, but
determination of relative windows is useful. There is increas-
ing concern that the window of opportunity in humans may
not be substantially longer than in smaller species. Notwith-
standing these concerns, the time window for efficacy in the
animal models must be clearly established. In the past, drugs
such as the N-methyl-D-aspartate antagonists cerestat and
selfotel demonstrated efficacy in animals for only a limited
after stroke onset.8 This limitation may have contributed to
their lack of efficacy in pivotal clinical trials. The optimal
duration of treatment in animals should also be examined to
guide clinical dosing because some neuroprotective strategies
could have paradoxical effects on outcome according to the
timing and duration of exposure.
In animal models, the time of the stroke or ischemic onset is
known precisely, whereas in humans this may not be the case. In
addition, in some animal models, a drug is given before the onset
of ischemia or at the time of reperfusion with little attention
given to administration at various times after reperfusion. In
humans, however, pharmacological agents are not routinely
given until hours after the ischemic event. Thus it may be
inappropriate to perform expensive clinical trials in which the
drug is administered, for example, at 3 hours after occlusion or
after reperfusion when the only preclinical animal work avail-
able shows the drug to be effective when given at the time of
arterial occlusion, reperfusion, or shortly thereafter. Thus a
careful assessment of the window of opportunity, that is, the
interval after the onset of ischemia or reperfusion when the drug
can be successfully administered, should be determined to
demonstrate whether the pharmacological agent can be effective
at various times after the ischemic event. For example, it would
be helpful to know if the drug was an effective neuroprotectant
at 15 minutes, 1 hour, 2 hours, and longer after onset of the
ischemic event in small-animal and perhaps large-animal
models.
Animal Models
There are multiple models of focal ischemia involving both
permanent and transient occlusion techniques.14,15 In general,
for small and large animals, permanent middle cerebral artery
occlusion (MCAO) models should be studied first, followed
by transient (reperfusion) models. However, it must be
recognized that the premature mortality rate is generally
greater with permanent occlusion models. An exception to
this recommendation is a situation in which the mechanism of
action of the drug suggests that it is likely to be effective only
with successful reperfusion.16 In the case of some nonhuman
primates, permanent occlusion of the proximal MCA may be
attended by significant mortality rates, as it is in humans. In
these cases, permanent MCA occlusion may not be suitable,
except under anesthesia. Permanent and transient model
studies should be initially completed in rats, then possibly in
cats or primates before beginning large clinical trials with
humans, especially with compounds that are novel, first-in-
class agents to determine if the drug is broadly effective.
Mouse models should be reserved for transgenic approaches
involving mechanisms of action.17 Gerbil models should be
avoided because many pharmacological agents act as pro-
tectants in gerbils but not in other species. There is 1
additional point concerning rat or mouse models that merits
concern. Certain strains are more sensitive to MCAO and
produce more sizable infarction volumes, whereas other
strains produce only a small infarction with MCAO.14 Thus it
is important to study the same strain of mouse or rat
throughout the experimental stage. It is critical that when
testing a potential neuroprotective agent in animal models,
the experiments should be performed in a randomized and
blinded fashion, as in clinical trials. Robustness of the
treatment effect is an important factor that determines
whether a compound will advance to clinical development.
Individual laboratories have developed ischemia models that
are designed to maximize detection of neuroprotection. In
some hands, the penumbral zone or potentially salvageable
region may be more substantial than in others. Therefore
there should be evidence of neuroprotective efficacy in 2 or
more laboratories, of which at least 1 should be independent
of the sponsoring company.
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Physiological Monitoring
Whether one uses small or large animals, appropriate physi-
ological monitoring is essential to maintain the animals
properly and to limit variability in infarct volume size. Blood
pressure, blood gases, hemoglobin, glucose, and CBF should
be monitored for as long as possible, although this may be
difficult in awake animals.14 Brain temperature is a critical
variable to be monitored and maintained as constant as
possible throughout the experimental protocol.18 This can be
measured indirectly in rats with a temporalis muscle temper-
ature probe. CBF can be measured with many techniques.
Laser Doppler flowmetry is commonly used in small animals
by many investigators. The laser Doppler signal can be
monitored before ischemia, during ischemia, and immedi-
ately after ischemia to ensure a proper reduction of CBF. A
reduction in the laser Doppler signal of $60% should be
achieved to ensure appropriate ischemia. In large-animal
models, there are other appropriate measures of CBF. In large
clinical trials, minor adverse changes in these physiological
variables, which may be discounted in small preclinical
pharmacological studies, could have a profound influence on
the trial result. Adverse events and potential drug interactions
should be considered. The therapeutic index in relation to
such changes should be defined.
Outcome Measures
In small-animal and large-animal models, at least 2 outcome
measures should be considered: functional response and
infarct volume. Outcome measures can include infarct vol-
ume, immunohistochemical analysis, neuropathology,
somatosensory-evoked potentials, electroencephalography,
and neurobehavior. Outcome measures must be monitored
during the acute phase (1 to 3 days) and the long term (7 to
30 days) if one is to examine the long-term effects of these
interventions. Acute outcome (typically reduced infarct vol-
ume) in a permanent or temporary occlusion model must be
evaluated and ameliorated by drug treatment because only in
acute treatment studies (typically up to 6 hours of intensive
monitoring) can all the physiological variables (blood pres-
sure, temperature, glucose) and clinical signs (signs of infec-
tion or vascular inflammation) that affect outcome be as-
sessed comprehensively from the onset of ischemia. Only
then can these variables be discounted as sources of artifact.
Many preclinical studies examined outcomes only at 24 hours
after the onset of ischemia. Several studies have now dem-
onstrated that it is a necessity to follow animals for much
longer time periods because if the compound is shown to be
initially effective with a short survival time, initial beneficial
effects may be lost over time.19,20 Long-term outcome, that is,
reduced infarct volume, should be evaluated to ameliorate
concerns that the drug merely slows the maturation of the
histopathological process. Long-term studies present greater
challenges for continuous monitoring of physiological vari-
able and assurance of adequate pharmacological design.
Functional recovery is a major end point in clinical trials.5,6 In
humans, the size of the lesion does not always correlate well
with functional impairment, although this correlation has been
shown to be more robust with diffusion-perfusion magnetic
resonance imaging.21 Although it may be difficult, it is desirable
to demonstrate that drugs improve functional outcome after
experimental ischemia. It is challenging to measure function and
behavior in brain-damaged animals, although techniques to
measure these outcomes are advancing. Furthermore, rodents,
for example, display extraordinary plasticity. If surrogate mark-
ers of outcome are used in clinical studies, these should be
examined in animal models. Replication of improved functional
outcome in at least a second species is likely to optimize the
chance of success in large-scale clinical trials. Evaluation in
larger species such as cats or primates is desirable rather than in
rodents only. There is always concern that some pathogenic
mechanisms may be disproportionately overrepresented (for
example, spreading depression) or underrepresented (for exam-
ple, collateral vasculature) in the rat. Moreover, as a direct
consequence of small brain (and lesion) size, “impressive”
volumetric tissue salvage (in percentage change) can be
achieved in rodents by small shifts in the infarction boundary.
Additional studies should be performed in animals in which
there is postischemic reperfusion to address the issue of whether
reperfusion complicates or confounds anti-ischemic efficacy
demonstrated with permanent ischemia. If a drug is intended to
be used solely in patients treated with thrombolysis, reperfusion
models may have greater validity than permanent occlusion
models.
Other Considerations: Target Populations
No animal model can exactly mimic stroke in humans.
However, unless the model has relevance to stroke in hu-
mans, for example, MCAO for permanent ischemia or autol-
ogous clot embolism for thrombolysis models, questions
regarding drug penetration to the ischemic tissue and phar-
macokinetic and time window issues will not be answered.22
The age and species of the animal used also probably
influence its relevance to stroke in humans. It is uncertain if
benefit in young, healthy animals can be extrapolated to
elderly, sick humans.
Sex Differences in Stroke
A potentially important consideration for the development of
pharmacological neuroprotective drugs may involve sex dif-
ferences in drug effectiveness. Recently it was demonstrated
that female rats have a markedly reduced infarct volume
compared with male rats with MCAO models, and ovariec-
tomized rats have infarct volumes that are similar in size to
male rats.23 Estrogen and perhaps even progesterone may
modulate in this response, and studies demonstrated that
exogenously administered estrogen reduces infarct volume
size in both male and female rats.24 This information may
lead to new therapeutic approaches to reduce infarct volume
and injury. Therefore it may be important to examine neuro-
protective drugs in male and female animals to separate
possible sex differences. In at least 1 clinical trial involving
tirilazad mesylate there were differences between men and
women regarding stroke outcome (Dr Edward Hall, personal
communication). The findings might be explained by differ-
ences in metabolism between men and women.
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Genetic Manipulation of Enzymes in
Animal Models
One new and exciting consideration concerning neuroprotec-
tion strategies involves genetic manipulation of endogenous
enzymes that may play a role in the mechanism of ischemic
injury. For example, mice with upregulated superoxide dis-
mutase (an endogenous oxygen radical scavenger) demon-
strate less infarction volume than wild-type mice when
exposed to MCAO.17 Neuronal nitric oxide synthase knock-
out mice also demonstrate less infarct volume than wild-type
mice.25 Additionally, this holds true for animals deficient in
poly (ADP-ribose) polymerase (PARP knockout).26 Would
the combination of the nitric oxide synthase knockout or
PARP knockout with upregulated superoxide dismutase dem-
onstrate an even greater reduction in infarct volume? The
manipulation of genes such as these and others purported to
be involved in mechanisms of injury or neuroprotection may
lead to unusual therapeutic approaches. Information derived
from these types of genetic studies may add eventually to the
stroke-neuroprotective armamentarium that will develop over
the next years.
Combined Pharmacological Agents
Because there are multiple mechanisms of neuronal injury
after ischemia, it is appropriate to consider using pharmaco-
logical agents that affect multiple mechanisms simulta-
neously. This has been referred to as the “cocktail” approach.
With the use of multiple neuroprotective therapies, each agent
could be given either simultaneously or in rapid succession,
allowing each agent to work on a different ischemic injury
mechanism. For example, the combined use of an oxygen
radical scavenger and excitatory amino acid antagonist may
provide greater neuroprotection than either agent alone. Few
prior studies evaluated multiple agent administration ap-
proaches. There is a great need for these studies in both
small-animal and large-animal models of ischemia to deter-
mine whether this treatment strategy has merit.27,28 Agents
that act as oxygen radical scavengers, excitatory amino acid
inhibitors, inhibitors of a variety of mediators of inflamma-
tion, calcium channel–blocking agents, hypothermia, and
TPA could be given simultaneously or in succession in an
attempt to improve outcome. The increasing use of
thrombolysis and likely benefit of neuroprotection when used
in combination with TPA requires that some examination of
potential interaction with thrombolytic and other agents
commonly used in acute stroke should be undertaken in
animals if relevant.
Recommendations to Clinicians on the
Evaluation of Preclinical Data With
Neuroprotective Drugs
In general terms, the ideal neuroprotective drug should
demonstrate efficacy in at least 2 species, in at least 2
laboratories that use different models, is effective in both
permanent and transient focal ischemia, and improves short-
term and long-term histological and functional outcomes,
even when administered several hours after the onset of
ischemia. If the site of action is the brain, the ideal drug
should achieve brain concentrations that rapidly equilibrate
with plasma, whereas this is not a requirement for agents that
target the vasculature such as antiadhesion molecules. There
should be a consistent minimum neuroprotective concentra-
tion across different species, allowing prediction of the
putative neuroprotective concentration in humans. A sigmoid
rather than bell-shaped dose-response curve within the ani-
mals is particularly desirable because the latter may imply
effects on physiological variables such as blood pressure that
could offset neuroprotective benefits. Data to guide the
duration of treatment should be available and based on the
pharmacokinetic profile and purported mechanism of action.
This ideal drug profile may not be attainable. The most
important points for clinical investigators to assess before
considering participation in a trial with a new neuroprotective
agent are: (1) an adequate dose-response curve with corre-
sponding serum levels defining at least the minimally effec-
tive and maximally tolerated doses in at least 1 species,
typically the rat; (2) time window studies showing benefit
when therapy is initiated at delayed time points after stroke
onset in animal models; (3) adequate physiological monitor-
ing was performed in randomized, blinded animal studies and
that treatment effects are reproducible in 2 laboratories, 1 of
which is independent of the sponsoring company; (4) out-
come measures should include both infarct volume and
functional assessment in both acute and long-term phase
animal studies; (5) initial studies should be done in smaller
species such as rodents subjected to permanent occlusion
models, unless the mechanism of drug action suggests that
reperfusion will be necessary for drug effect. In this case,
clinical development probably will be linked to reperfusion
therapy. A second larger species (cats, primates) should be
strongly considered for further preclinical assessment for
novel, first-in-class drugs; (6) the data should be published or
submitted for review in a peer-reviewed journal.
Recommendations Regarding Preclinical
Development of Stroke Recovery Drugs
Patients with ischemic stroke may make significant sponta-
neous recovery after their event. Recovery of some neurolog-
ical impairments, such as speech, language, neglect, balance,
and gait is common. Other neurological impairments, such as
a dense visual field abnormality or hemiplegia, may not
recover substantially. Recovery may relate to the size and
location of the cerebral infarction as well as the initial degree
of clinical deficit. The mechanisms promoting functional
recovery after ischemic stroke are not entirely clear but most
likely depend on functional and/or structural reorganization
of the remaining intact brain. Studies in humans with stroke
show that recovery may be robust for at least the first 3
months after the stroke, but further recovery may continue
thereafter.29 This prolonged time window of opportunity to
intervene on the stroke recovery process offers a substantial
and currently unexploited opportunity for drug development.
In animal models, several classes of compounds have already
shown potential as stroke recovery–enhancing drugs. These
include monoamine agonists such as amphetamines and
neurotrophic growth factors. The future development of
stroke recovery drugs will be dependent on the establishment
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of convenient and reproducible animal models and appropri-
ate clinical trial design.
Animal Models
Rat Models
A standard rodent model for post–stroke recovery studies has
yet to be established. The histopathology and behavioral
deficits seen with global ischemia are quite distinct, and
therefore the focus of these recommendations will be models
of focal brain ischemia. Many of the models used for acute
stroke neuroprotection studies, such as the intra-arterial
suture occlusion models, result in massive hemispheric in-
farction and short animal survival times.14 For stroke recov-
ery studies, more limited infarction must be produced, usually
by direct surgical occlusion of the proximal MCA (the so
called “Tamura” method).30,31 Such surgery in rats results in
considerable infarction in the dorsolateral cerebral cortex and
underlying striatum with prolonged survival. The cortical
areas involved subserve forelimb and hindlimb function that
control sensorimotor behavior in the contralateral limbs.
Standard methods have yet to be established regarding mea-
surements of animal behavioral deficits and their recovery after
focal infarction in rodents. However, there are a number of tests
of sensorimotor function that can be used. Methods to assess
sensorimotor recovery of the limbs include paw-placing
tasks.30,32,33 These tests assess the ability of the animal to place
the paws on a table top in response to visual, tactile, whisker, and
proprioceptive stimulation. These placing tests are highly sub-
jective and observer dependent, and the results may be difficult
to replicate. In addition, these tests depend heavily on the
activation state of animals; highly agitated animals cannot be
tested well with these methods. Other methods for assessing
sensorimotor recovery in rats include the foot-fault test, beam
walking, and beam-balance tests.31,34,35 These tests have been
used successfully by several investigators, in particular to show
the recovery-promoting effects of amphetamine treatment after
cortical injury in rats. Other tests include those of spontaneous
limb use, such as the cylinder test developed by Schallert and
colleagues.30,36 This test assesses the ability of the animal to
spontaneously use the forelimbs in rearing to explore the inner
walls of a narrow glass cylinder. Normally, the animal uses each
forelimb approximately half the time in exploratory movements.
This balance is changed when there is unilateral brain injury, and
the animal shows relatively less exploratory movements with the
contralateral (impaired) limb. Another approach involves reach-
ing tests developed by Kolb et al.37 In these tests, animals are
food deprived and trained with an apparatus that assesses their
ability to pick up food pellets with one limb or the other. All of
the above tests can be videotaped for blind scoring of animal
behavior and for archiving the data.
These behavioral tests were used in studies that show the
efficacy of various classes of drugs that promote poststroke
recovery in rodents. In particular, the foot-fault and beam-
walking tasks demonstrated the impact of amphetamine in
enhancing recovery.34,35 Paw-placing and reaching tasks were
used in studies that show the efficacy of neurotrophic growth
factors in enhancing stroke recovery.10,30,37, Generally, these
behavioral methods show a marked deficit in functioning of the
contralateral forelimb and hindlimb after stroke. Depending on
the test used, there is a slow, steady, and incomplete recovery of
function over the next month or so. Depending on the model
used, amphetamines or growth factors were observed to accel-
erate the rate and enhance the maximal degree of recovery.30,35
In the studies in which amphetamines were used, the adminis-
tration was systemic because these small molecules are expected
to cross the blood-brain barrier. In the case of growth factor
treatment, studies used the intracerebral (intraventricular or
intracisternal) administration because these large proteins are not
expected to easily cross the blood-brain barrier.
In addition to the tests of sensorimotor abilities in rats, a
number of cognitive tests are also available. The prototype test is
the Morris water maze, which assesses the animal’s memory (by
finding its way to a submerged platform within a large water
tank).37 The animal navigates to this platform by means of
external cues. The behavior can be learned within several trials
over several days. The ability of an animal to learn and retain
this information is considered an index of memory.
Primate Models
There may be a distinct role for primate models in the stroke
recovery field. There are a number of dissimilarities between
the rodent brain and that of humans and nonhuman primates
that may lead to differences in response to an identical
ischemic insult.38 Therefore it is difficult to know how to
scale up dosing regimens from rodents to humans. This
includes both dose and duration of drug administration. As
noted above, recovery in rodent models occurs rapidly over
the first few weeks after stroke. Recovery in humans with
stroke may occur over a longer time, up to several months
after stroke. Thus timing and duration of drug administration
for humans is not easily extrapolated from rat models. A
similar concern applies to drug dosage. Some drugs, for
example, those that are given systemically, can be adjusted by
body weight. On the other hand, other stroke recovery
treatments, such as proteins and growth factors, which must
be given intracerebrally, might be scaled up by brain surface
area or volume. It may be difficult to make the transition from
rodent models to humans without the intermediate step of
primate models and the development of a noninvasive mech-
anism to deliver the drug to patients.
There has been more than 35 years of experience with
experimental preparations of MCAO in the nonhuman primate
(baboon), which allows it to be considered a standard format for
fundamental studies, exploratory studies, and preclinical work in
academia and industry.39–43 However, as with rodents, currently
there are no standardized, well-accepted models of stroke recov-
ery in primates, although limited experience exists with baboons.
Perhaps the most extensive primate recovery work to date has
been done by Nudo and colleagues38 in squirrel monkeys. These
investigators demonstrated functional reorganization of the sen-
sorimotor cortex in monkeys after small cortical infarcts. How-
ever, strokes were small, and there was considerable spontane-
ous recovery. An optimal animal model for testing stroke
recovery drugs would encompass some but not complete recov-
ery, as this would approximate the human condition.
Ideally, stroke recovery studies in primates might be done
with a gyrencephalic species, similar to humans, for example,
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macaque monkeys. In addition, however, there are other models
in less developed primates, for example, lissencephalic brains,
such as in marmosets. Behavioral studies in marmosets receiving
the neuroprotective drug clomethiazole were recently reported.44
Recommendations
Given the current state of knowledge, the following recom-
mendations can be made concerning the preclinical develop-
ment of stroke recovery drugs.
Rodent Models
Putative stroke recovery drugs should be tested in rodents
with models of focal cerebral infarction that permit extended
recovery. Recovery of sensorimotor function of the contralat-
eral limbs and cognitive function should be examined. The
results should be independently replicated in at least 2
laboratories. Studies should be carried out in a blinded-
randomized fashion. After behavioral assessments, animals
should be killed and brain studies for histological analysis
and infarct volume performed. Incorporating the suggestions
made in the section on acute stroke treatment, such studies
might also be done in models of permanent occlusion versus
reperfusion and in male as well as female animals.
In stroke recovery studies, monitoring of physiological pa-
rameters during the stroke surgery is less important than it is in
acute stroke studies. Rat behavioral studies should be performed
for at least 1 month after infarction.
Primate Studies
It is reasonable to explore stroke recovery drugs that show
promise in rats, subsequently in primate models. These might
include established behavioral models in marmosets or squir-
rel monkeys as well as tests of sensorimotor and cognitive
function in higher-order primates such as macaques or
baboons.
Route of Drug Administration
The route of administration should be carefully considered in
evaluating a stroke recovery drug. Many putative treatments,
for example, polypeptide growth factors, might not easily
cross the blood-brain barrier, and intracisternal or intraven-
tricular administration may be necessary, although this prob-
ably is not a feasible approach for clinical development.
Conversely, small molecules such as amphetamines and other
monoamine agonists might cross the blood-brain barrier more
easily and be appropriate for intravenous administration.
Toxicology
Clearly, when an effective drug and route of administration is
demonstrated, careful toxicological studies in several species,
including both intact animals and animals with stroke, are
indicated in the drug development process.
Dose-Response Studies
As in the development of acute stroke treatments, careful
dose-response studies are necessary for planning of future
clinical trials with these agents.
Time Window
As in acute stroke studies, the time window of opportunity for
treatment is an important variable in preclinical models that
precede clinical development. The time window for admin-
istration of stroke recovery drugs is likely to be longer than
that for acute stroke treatments by perhaps days after stroke
onset. Such time window considerations must be carefully
considered when designing clinical trials.
Clinical Development of Stroke
Recovery Drugs
Although the preclinical assessment of stroke recovery drugs
may be more difficult than that for acute stroke neuroprotec-
tive agents, the clinical development of stroke recovery drugs
is likely to be easier. The time window of entry into a stroke
recovery study will presumably be considerably longer than
that for acute stroke studies. This prolonged time window to
entry will offer investigators the opportunity to derive de-
tailed baseline information on patients. Such information
might include detailed testing of neuropsychological param-
eters, motor function, and functional capacities. In particular,
scales such as the Functional Independence Measure, the
Fugl-Meyer scale, depression rating scales, and formal neu-
ropsychological test batteries can be given before and after
treatment. Thus detailed baseline information can be obtained
on every patient and compared with detailed follow-up
information on each patient. In this sense, each patient can
serve as his or her own control, and meaningful change scores
can be computed over time. Another advantage for stroke
recovery studies is that placebo responders can be more
effectively excluded from these studies. Patients who are
rapidly improving during the first few days after a stroke can
be excluded. Recovery studies not only can use functional
outcome to assess therapeutic responses but can evaluate
treatment effects on quality of life.
In summary, there is currently a substantial unexplored
opportunity for the development of new pharmacological agents
and other treatments to enhance functional recovery after stroke.
Clinical investigators must pay careful attention to and be able to
critically assess the data from preclinical studies.
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